^
1d
Enrollment open • Combination therapy
|
temozolomide • Verzenio (abemaciclib)
2d
Long-Term Response to CDK4/6 Inhibitor for Multiple Metastases of Breast Cancer (PubMed, Gan To Kagaku Ryoho)
Surgery was not possible due to comorbidities, so fulvestrant(500 mg/month)+denosumab(120 mg/month)was started. Furthermore, as the tumor markers were elevated, abemaciclib(300 mg/day)was added, which resulted in a decrease in the tumor markers...During the course of treatment, the tumor markers rose again, so the dose was increased to 250 mg/day, which resulted in a decrease in the tumor markers and good tolerability. At present, 36 months after the start of treatment, long SD has continued, no adverse events of grade 3 or higher have been observed, and the drug has been well tolerated.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HER-2 negative • PGR positive • HER-2 negative + AR positive + ER positive • HER-2 negative + ER positive • HER-2 negative + PGR positive
|
Verzenio (abemaciclib) • fulvestrant • Prolia (denosumab)
3d
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=28, Recruiting, Memorial Sloan Kettering Cancer Center | Not yet recruiting --> Recruiting
Enrollment open • Metastases
|
Verzenio (abemaciclib)
4d
A Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer. (PubMed, Clin Cancer Res)
The combination of abemaciclib and fulvestrant has promising activity with durable responses in advanced or recurrent EC; a randomized trial is planned.
P2 data • Journal • MSi-H Biomarker • Metastases
|
ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CCND1 (Cyclin D1)
|
HR positive • MSI-H/dMMR • PGR expression
|
Verzenio (abemaciclib) • fulvestrant
5d
Dormancy Leading to Late Recurrence in Breast Cancer: A Case of Hormone Receptor-Positive Supraclavicular Metastasis 10 Years After the Initial Treatment. (PubMed, Cureus)
Her treatment was adjusted to include Faslodex (fulvestrant) and Verzenio (abemaciclib), followed by the surgical resection of the metastatic lymph node. Understanding dormancy and reactivation mechanisms is essential for guiding clinical decisions. Prioritizing individualized follow-up strategies and refining treatment protocols will be key to improving patient outcomes and maintaining quality of life.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
|
ER positive • HR positive • HER-2 negative • PGR positive • EGFR positive
|
Verzenio (abemaciclib) • fulvestrant
8d
Real-world effectiveness of CDK 4/6 inhibitors in estrogen-positive metastatic breast cancer. (PubMed, BJC Rep)
This study confirms first-line CDK 4/6i effectiveness, with abemaciclib and ribociclib showing prolonged PFS vs. palbociclib. This study could not confirm a ranking of the three CDK 4/6i.
Journal • Real-world evidence • Real-world effectiveness • Real-world • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
9d
TACTIVE-U Sub-Study A: TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A) (clinicaltrials.gov)
P1/2, N=36, Active, not recruiting, Pfizer | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Sep 2025 | Trial primary completion date: Dec 2025 --> Sep 2025
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Verzenio (abemaciclib) • vepdegestrant (ARV-471)
10d
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas (clinicaltrials.gov)
P1/2, N=55, Recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2026 --> Dec 2029 | Trial primary completion date: Dec 2025 --> Dec 2028
Trial completion date • Trial primary completion date
|
NF1 (Neurofibromin 1)
|
NF1 mutation
|
Verzenio (abemaciclib)
13d
New P3 trial • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
TP53 mutation • ER mutation • ER Y537S • ER D538G • ESR1 mutation • ER Y537N • ER L536Q • ER Y537C
|
Verzenio (abemaciclib) • fulvestrant • Fablyn (lasofoxifene)
17d
RESOLVE: Abemaciclib + Letrozole +/- Metformin or Zotatifin in Endometrial or Low-Grade Serous Ovarian Cancer (clinicaltrials.gov)
P2, N=130, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Aug 2029 --> Aug 2030 | Trial primary completion date: Aug 2026 --> Aug 2027
Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy
|
ER (Estrogen receptor)
|
ER positive
|
Verzenio (abemaciclib) • letrozole • zotatifin (eFT226) • metformin • samotolisib (LY3023414)
17d
TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer (clinicaltrials.gov)
P2, N=90, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2026 --> Jun 2025
Enrollment closed • Trial primary completion date
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
tamoxifen • Verzenio (abemaciclib) • letrozole • anastrozole • exemestane
17d
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer (clinicaltrials.gov)
P1, N=28, Not yet recruiting, Memorial Sloan Kettering Cancer Center
New P1 trial • Metastases
|
Verzenio (abemaciclib)
18d
Fasting-mimicking diet potentiates anti-tumor effects of CDK4/6 inhibitors against breast cancer by suppressing NRAS- and IGF1-mediated mTORC1 signaling. (PubMed, Drug Resist Updat)
Our data demonstrate that FMD overcomes resistance and potentiates the anti-tumor effect of CDK4/6i by inhibiting mTORC1 signaling via lowering the levels of IGF1 and RAS, providing the rationale for clinical investigation of a potential FMD-CDK4/6i strategy in breast cancer.
Journal
|
NRAS (Neuroblastoma RAS viral oncogene homolog) • IGF1 (Insulin-like growth factor 1)
|
Verzenio (abemaciclib)
22d
Clinical
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Oncotype DX Breast Recurrence Score®Test
|
Verzenio (abemaciclib) • letrozole
23d
Patient with hormone receptor‑positive Her2‑negative metastatic breast cancer with visceral crisis with good response to abemaciclib and letrozole: A case report and review of the literature. (PubMed, Mol Clin Oncol)
Furthermore, the side effects were manageable and no dose reductions were necessary during treatment. These findings suggest that the combination of CDK4/6i and ET in the treatment of HR+/HER2-advanced breast cancer cannot be underestimated.
Review • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
Verzenio (abemaciclib) • letrozole
23d
Predictors of abemaciclib discontinuation in patients with breast cancer: a multicenter retrospective cohort study. (PubMed, BMC Cancer)
Patients with lower body weight are more susceptible to the adverse events of abemaciclib, increasing their risk of treatment discontinuation. In such patients, strict monitoring of adverse events and consideration of more frequent medical visits are necessary from the start of abemaciclib therapy.
Retrospective data • Journal
|
CDK4 (Cyclin-dependent kinase 4)
|
Verzenio (abemaciclib)
27d
Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase III randomized monarchE study. (PubMed, Ther Adv Med Oncol)
These results represent the first full report of a CDK4/6 inhibitor in Chinese patients with EBC and support the positive benefit-risk profile of adjuvant abemaciclib + ET in Chinese patients. ClinicalTrials.gov identifier: NCT03155997 (first posted: May 16, 2017).
P3 data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Verzenio (abemaciclib)
1m
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study. (PubMed, Gynecol Oncol)
Imlunestrant, as monotherapy and combined with abemaciclib, has a manageable safety profile with preliminary evidence of antitumor activity in patients with ER+ EEC.
P1 data • Journal • Metastases
|
ER (Estrogen receptor)
|
ER positive
|
Verzenio (abemaciclib) • fulvestrant • imlunestrant (LY3484356)
1m
Establishment of matched bladder cancer PDX and PDX-derived organoid model and evaluation of anti-tumor efficacy of abemaciclib. (PubMed, Clin Transl Oncol)
Our research provided compelling evidence attesting to the reliability and potential of PDX and PDXO models in the realm of precision medicine. These models are instrumental in identifying patients who are likely to respond favorably to a specific drug treatment.
Journal
|
CCND1 (Cyclin D1) • CDK4 (Cyclin-dependent kinase 4)
|
CCND1 expression
|
Verzenio (abemaciclib)
1m
New trial • Adherence
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Verzenio (abemaciclib)
1m
Trial completion
|
HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
|
HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative • PTEN mutation + HR positive
|
Avastin (bevacizumab) • Tecentriq (atezolizumab) • tamoxifen • Verzenio (abemaciclib) • fulvestrant • ipatasertib (RG7440) • exemestane • Jingzhuda (entinostat)
1m
JUNIPER: A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer (clinicaltrials.gov)
P3, N=453, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date • Metastases
|
KRAS (KRAS proto-oncogene GTPase)
|
KRAS mutation
|
erlotinib • Verzenio (abemaciclib)
1m
Real-world outcomes in patients with brain metastases secondary to HR+/HER2- MBC treated with abemaciclib and local intracranial therapy. (PubMed, Oncologist)
In this real-world study of patients diagnosed with brain metastases and initiating abemaciclib, most patients received radiation/local surgery to the brain before abemaciclib initiation. Although the outcomes in this real-world study are encouraging, it is unclear if the benefit was due to local therapy, abemaciclib, or the combination, and causality cannot be inferred. Further prospective clinical studies are needed to confirm the clinical benefit of this approach.
Journal • Real-world evidence • Real-world
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Verzenio (abemaciclib)
1m
Classic Kaposi sarcoma: Diagnostics, treatment modalities, and genetic implications - A review of the literature. (PubMed, Acta Oncol)
While advancements in CKS treatment offer hope, further studies on immunotherapy are warranted to broaden the therapeutic options, such as anti-bromodomain or BPTF-targeted therapy.
Review • Journal • IO biomarker
|
MDM2 (E3 ubiquitin protein ligase) • BPTF (Bromodomain PHD Finger Transcription Factor)
|
Verzenio (abemaciclib)
1m
The efficacy and safety of CDK4/6 inhibitors combined with endocrine therapy versus endocrine therapy alone in the adjuvant treatment of patients with high-risk invasive HR+/HER2-early breast cancer: A comprehensive updated meta-analysis of randomized clinical trials. (PubMed, Breast)
The findings of this paper demonstrate a significant improvement in iDFS when ET is combined with CDK4/6i, compared to ET alone. Specifically, treatments with abemaciclib and ribociclib showed notable enhancements in dRFS.
Clinical • Retrospective data • Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
1m
Eligibility for Adjuvant Cyclin-Dependent Kinase 4/6 Inhibitors in Endocrine Receptor-Positive and HER2-Negative Early Breast Cancer by Age and Type of Surgery. (PubMed, Cancers (Basel))
Significantly higher eligibility rates were observed in patients who underwent a mastectomy, >70 years and ≤40 years for adjuvant abemaciclib and ribociclib, and in patients >80 years for ribociclib. A higher discontinuation rate for abemaciclib was reported in patients aged ≥65 years and it can be assumed that discontinuation rates may increase in even older patients. If the results of the NataLEE trial translate into clinical practice, the number of patients potentially eligible for adjuvant CDK4/6 inhibitors may increase, especially in the elderly population.
Journal • Surgery
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 positive • ER positive • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
|
Verzenio (abemaciclib) • Kisqali (ribociclib)
1m
Radiation hepatitis after postmastectomy radiation therapy for early breast cancer: difficult to differentiate from drug-induced liver injury caused by abemaciclib. (PubMed, Int Cancer Conf J)
Spontaneous improvement allowed us to resume ABM treatment. Clinicians may need to consider radiation hepatitis as a potential cause of hepatic dysfunction in patients who underwent PMRT, along with drug-induced liver injury.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • EGFR positive
|
Verzenio (abemaciclib)
1m
The prognostic utility of ctDNA detection in the monarchE study of adjuvant treatment with abemaciclib in combination with endocrine therapy (ET) in HR+, HER2-, node-positive, early high-risk breast cancer (DGHO 2024)
In a pt subset from monarchE enriched for IDFS events, ctDNA detection was relatively infrequent (<20%); however, its detection at any time during the 24 months of study therapy was adversely prognostic. As compared to pts who had remaining ctDNA positive (+), pts who had clearance of ctDNA on therapy had lower risk of IDFS events, but the event risk still remained clinically meaningful in these pts.
Clinical • Combination therapy • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2)
|
Signatera™
|
Verzenio (abemaciclib)
1m
Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+/HER2- advanced breast cancer: Final results of the randomized phase III MONARCH plus trial. (PubMed, Chin Med J (Engl))
Abemaciclib plus ET led to improvements in PFS and ORR, a manageable safety profile, and sustained HRQoL, providing clinical benefit without a high toxicity burden or reduced quality of life.
P3 data • Journal • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Verzenio (abemaciclib) • fulvestrant • letrozole • anastrozole
1m
Trial completion date
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • letrozole • anastrozole • exemestane • camizestrant (AZD9833) • saruparib (AZD5305)
2ms
MONARCH 3: A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer (clinicaltrials.gov)
P3, N=493, Active, not recruiting, Eli Lilly and Company | Trial completion date: Dec 2024 --> Dec 2025
Trial completion date • Metastases
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Verzenio (abemaciclib) • letrozole • anastrozole
2ms
New P2 trial • Metastases
|
Lynparza (olaparib) • Tagrisso (osimertinib) • carboplatin • gefitinib • gemcitabine • paclitaxel • temozolomide • tamoxifen • Verzenio (abemaciclib) • pemetrexed • fulvestrant • letrozole • pegylated liposomal doxorubicin • exemestane • Myocet (non-pegylated liposomal doxorubicin) • Duomeisu (pegylated liposomal doxorubicin)
2ms
DISCORDANT: A Randomised Trial Comparing Trastuzumab Deruxtecan to CDK4/6 Inhibitors in Non-luminal A, ER-positive/HER2-negative Metastatic Breast Cancer (clinicaltrials.gov)
P3, N=504, Not yet recruiting, Danish Breast Cancer Cooperative Group | Phase classification: P4 --> P3 | N=250 --> 504
Phase classification • Enrollment change
|
tamoxifen • Enhertu (fam-trastuzumab deruxtecan-nxki) • Verzenio (abemaciclib) • Kisqali (ribociclib) • exemestane
2ms
Screening of differential gene expression patterns through survival analysis for diagnosis, prognosis and therapies of clear cell renal cell carcinoma. (PubMed, PLoS One)
Then we detected 10 repurposable drug molecules (Irinotecan, Imatinib, Telaglenastat, Olaparib, RG-4733, Sorafenib, Sitravatinib, Cabozantinib, Abemaciclib, and Dovitinib.) by molecular docking with KGs-mediated receptor proteins. Their ADME/T analysis and cross-validation with the independent receptors, also supported their potent against ccRCC. Therefore, these outputs might be useful inputs/resources to the wet-lab researchers and clinicians for considering an effective treatment strategy against ccRCC.
Journal • PARP Biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • SERPINA5 (Serpin Family A Member 5)
|
Lynparza (olaparib) • sorafenib • imatinib • Verzenio (abemaciclib) • Cabometyx (cabozantinib tablet) • irinotecan • dovitinib (TKI258) • telaglenastat (CB-839) • sitravatinib (MGCD516) • RG4733
2ms
Real-World Data with CDK4/6 Inhibitors-A Single Center Experience from Croatia. (PubMed, J Pers Med)
Our study provides the RWD with the use of CDK4/6 inhibitors in the treatment of metastatic HR+/HER2- breast cancer. To our best knowledge, there are limited RWD regarding CDK 4/6 inhibitors use in western Balkan; thus, our study provides valuable data from everyday clinical practice for this region of Europe, bridging the gap between randomized clinical trials and clinical reality in western Balkan.
Clinical • Journal • Real-world evidence • Real-world
|
HER-2 (Human epidermal growth factor receptor 2)
|
HER-2 negative
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib)
2ms
Therapeutic Prospects of Abemaciclib for Patients with Endometrial Cancer. (PubMed, Curr Oncol)
While the therapeutic role(s) of abemaciclib was fairly established in a subset of patients with advanced/metastatic BC through the pivotal MONARCH trials, its attributes and clinical utility in EC are limited. Thus, based on some promising pre-clinical/translational insights and a recent phase II study, we highlight abemaciclib's properties and potential clinical usefulness in patients with EC, particularly in recurrent estrogen-receptor-positive cases.
Review • Journal
|
ER (Estrogen receptor) • CDK4 (Cyclin-dependent kinase 4) • CDK6 (Cyclin-dependent kinase 6)
|
ER positive
|
Verzenio (abemaciclib)
2ms
Enrollment closed • Circulating tumor DNA
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
ER positive • HR positive • HER-2 negative • ER mutation • ESR1 mutation • HR positive + HER-2 negative • PTEN mutation + HR positive • HER-2 negative + ER positive • HER-2 negative + ER positive + ESR1 mutation • HER-2 negative + HR positive + ESR1 mutation
|
Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • letrozole • anastrozole • camizestrant (AZD9833)
2ms
Trial completion • Combination therapy • Metastases
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor) • MSI (Microsatellite instability)
|
MSI-H/dMMR • HER-2 overexpression • HER-2 negative
|
Verzenio (abemaciclib) • Cyramza (ramucirumab) • merestinib (LY2801653) • lodapolimab (LY3300054) • LY3321367
2ms
CAMPFIRE: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (clinicaltrials.gov)
P2, N=105, Recruiting, Eli Lilly and Company | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
Trial completion date • Trial primary completion date
|
gemcitabine • docetaxel • temozolomide • Verzenio (abemaciclib) • cyclophosphamide • Cyramza (ramucirumab) • vinorelbine tartrate • Navelbine oral (vinorelbine tartrate oral)
2ms
Challenges of Renal Function Assessment in Breast Cancer Patients Treated With Abemaciclib: A Case Report. (PubMed, Cureus)
Healthcare providers should be aware of abemaciclib's effect on serum creatinine but should not eliminate the possibility of actual kidney injury. Alternative biomarkers for GFR assessment are recommended, although the usefulness of cystatin-C in patients receiving abemaciclib should be investigated in greater depth.
Journal
|
HER-2 (Human epidermal growth factor receptor 2)
|
HR positive • HER-2 negative
|
Verzenio (abemaciclib)